Remix Therapeutics is a biotechnology company focused on developing small molecule therapies to target RNA-modulated gene expression for the treatment of cancer and genetic diseases.

Remix Therapeutics

Remix launched in 2020 with a vision to transform patient's lives through modulation of RNA processing. Our breakthrough science provides a path to identify small molecules that impact the expression of disease driving mRNAs and proteins. We take on the challenge of addressing drug targets in diseases of high unmet medical need to bring new therapeutic options to patients. Remix has a commitment to demonstrate the highest levels of scientific integrity with urgency because those patients are counting on us to deliver. With an in-house technology platform built from scratch, we have rapidly generated multiple drug discovery programs that are advancing towards the clinic.

Atlas Venture

The Column Group

Foresite Capital

Alexandria Venture Investments

ARCH Venture Partners

Casdin Capital

Surveyor Capital

Willett Advisors LLC

WTT Investment

Kicking off the year with two exciting announcements.  Here's to an amazing 2024!🥂🎉 View our press releases here: https://bit.ly/3RLgQ5y

Remix CEO Peter Smith will be presenting at the JP Morgan Conference January 10th at 10:30am PT. View press release here: https://bit.ly/48oLcSa

Check out our new website and learn about our innovative scientific approaches, the Remix culture, and our mission to bring new RNA processing modulators to patients. #TrueToOurRNA Visit our site: https://bit.ly/3Tq0m5j

Spirits were bright as #Remixers swapped gifts while donning the ugliest (and prettiest!) of sweaters in our annual Yankee Swap yesterday! 🎁 ❄ #RemixingTogether

📢 Remix Therapeutics Head of Drug Discovery, Dominic Reynolds, is looking forward to discussing the challenges of small molecule-RNA drug discovery and excited to share how the REMaster platform finds cell-active ligands with functional activity at the upcoming RNA-Targeted Drug Discovery Meeting in Boston!📢 Read full press release here: https://bit.ly/4acn5b5

COM:REMIXTX

Remix Therapeutics

Financials Not Available